GlassScriptPhysician profile
Eduardo Cutie
NPI 1932159670
$11,979.49
in general payments reported to CMS, 2019-2025
49 companies · $1,093 in 2025
The $1,093 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,161 · 2020: $1,335 · 2021: $3,024 · 2022: $1,849 · 2023: $1,322 · 2024: $1,196 · 2025: $1,093.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,611.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,611.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,864.30 | 2021-2025 | Qulipta, Ubrelvy, Botox |
| Neurocrine Biosciences, INC. | $1,214.19 | 2019-2025 | Ingrezza, Ongentys |
| Ucb, INC. | $1,025.77 | 2019-2025 | Fintepla, Briviact, Nayzilam |
| Amgen INC. | $705.63 | 2019-2022 | |
| Lilly USA, LLC | $597.75 | 2019-2024 | Amyvid, Kisunla, Emgality |
| Teva Pharmaceuticals USA, INC. | $592.18 | 2019-2025 | Austedo Xr, Austedo Xr |
| Adamas Pharmaceuticals, INC. | $549.35 | 2019-2021 | |
| Allergan, INC. | $534.70 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $526.13 | 2021 | |
| Sunovion Pharmaceuticals INC. | $430.49 | 2019-2022 | |
| Biogen, INC. | $400.89 | 2021-2022 | |
| Argenx US, INC. | $326.19 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Acorda Therapeutics, INC | $264.93 | 2019-2023 | Inbrija |
| Novartis Pharmaceuticals Corporation | $250.70 | 2019-2021 | |
| Merz Pharmaceuticals, LLC | $238.33 | 2022-2025 | Xeomin, Inbrija |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eduardo Cutie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.